Nexien’s Drug Development Activities

Nexien is developing advanced parenteral formulations and drug delivery systems, as well as precision oral and sublingual tablet technology for the use of cannabinoid API's as standalone or adjunct therapies.

Nexien BioPharma’s drug development strategy consists of:

  • The treatment of convulsive disorders, particularly epilepsy and refractory epilepsy. Cannabinoid treatments have shown efficacy in epilepsy conditions which do not respond well to the current standard of care.
  • The acute treatment during exposure to organophosphorus nerve agents , including sarin gas.
  • The treatment of various symptoms related to myotonic and muscular diseases such as dystrophia diseases.
  • The treatment of  various symptoms related to lipidosis, which are genetic disorders which are characterized by defects of the digestive system that impair the way the body uses dietary fat.
  • The treatment of  various symptoms related to lipofuscinosis, in particular neural ceroid lipofuscinosis and macular degeneration associated with lipofuscinosis, which is any disorder associated with the abnormal storage of lipofuscins. Lipofuscins is a yellow to brownish pigment granule found in the muscle, heart, liver, kidney, adrenal, retina and nerve cells undergoing slow regressive changes and accumulating in lysomes with age.
  • The treatment of restless legs syndrome. Restless leg syndrome (RLS) otherwise known as Willis-Ekbom Disease and Wittmaack-Ekbom Syndrome is a term used to describe a neurological sensory disorder that also interferes with sleep and is thus also considered a sleep disorder.
  • Sexual health affecting both males and females.